Abstract
Bone marrow stromal cells (BMSCs) include a subset of stem cells that are considered promising for developmental studies and therapeutic applications. While it is appreciated generally that BMSC populations can exhibit morphological and functional heterogeneity upon in vitro culture expansion, the potential for heterogeneity within a single colony forming unit–generated ostensibly from a single mother cell–is less explored but is critical to design of both fundamental studies and cell therapy production. Here we observed BMSC colony formation in real time via time lapsed optical imaging and analysis, to quantify whether and how heterogeneity emerged over multiple cell divisions spanning the duration of a typical colony formation unit assay. These analyses demonstrate that such colonies are neither homogeneous subpopulations of stem cells nor necessarily derived from single originating cells. While the mechanisms for and causes of this intracolony heterogeneity are not understood fully, we further demonstrate that extensive cell-cell contacts do not correlate with senescence, but that media exchange was concurrent with diversification in even the most uniform single-cell-derived colonies. These direct quantitative observations and visualizations of colony formation provide new insights that are motivated by significant implications for both basic research and stem cell-based therapies.
Highlights
Bone marrow stromal cells (BMSCs), a subset of which are characterized as multipotent mesenchymal stem cells, are considered potential cell therapies for diverse medical conditions– from bone tissue regeneration to autism and Parkinson’s disease [1,2,3]
Such culture-expanded BMSC populations have been implemented in over 600 clinical trials since 1995. Despite these advances at the lab scale and in ongoing clinical trials, we are aware of no therapies to date that have been approved by the U.S Food & Drug Administration for delivery of BMSCs or putative mesenchymal stem cells
Intercolony heterogeneity can result from multiple progenies within a putative clone It is well documented that BMSC colonies derived from a given donor vary substantially from each other in terms of colony size, confluency, and multilineage potential [5,19,20,21,22,23]
Summary
Bone marrow stromal cells (BMSCs), a subset of which are characterized as multipotent mesenchymal stem cells, are considered potential cell therapies for diverse medical conditions– from bone tissue regeneration to autism and Parkinson’s disease [1,2,3]. Such culture-expanded BMSC populations have been implemented in over 600 clinical trials since 1995 Despite these advances at the lab scale and in ongoing clinical trials, we are aware of no therapies to date that have been approved by the U.S Food & Drug Administration for delivery of BMSCs or putative mesenchymal stem cells The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have